Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.26 -0.04 (-0.14%) 7:04 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.26 -0.04 (-0.14%) 7:04 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Pfizer (PFE) concluded the recent trading session at $27.93, signifying a -0.43% move from its prior day's close.
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
by Zacks Equity Research
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
CHMP Endorses Moderna's (MRNA) mRNA-based RSV Vaccine
by Zacks Equity Research
If approved, the RSV vaccine will be Moderna's (MRNA) second approved product in the European Union.
CDC Narrows Age Recommendation for Use of RSV Vaccine
by Zacks Equity Research
The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
by Zacks Equity Research
Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Pfizer (PFE) closed at $27.99 in the latest trading session, marking a -1.3% move from the prior day.
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
by Zacks Equity Research
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
by Zacks Equity Research
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
by Zacks Equity Research
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $27.41, marking a +1.59% move from the previous day.
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
by Zacks Equity Research
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
by Kinjel Shah
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
by Zacks Equity Research
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Pfizer (PFE) closed at $27.66 in the latest trading session, marking a -1.32% move from the prior day.
Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal
by Zacks Equity Research
Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.
Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
by Zacks Equity Research
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
by Zacks Equity Research
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.